Stock CELLECTAR BIOSCIENCES INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Cellectar Biosciences Inc Nasdaq

Equities

US15117F3029

Pharmaceuticals

Business Summary

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

Managers

Managers TitleAgeSince
James V. Caruso CEO
 Chief Executive Officer 65 15-06-14
Chad J. Kolean DFI
 Director of Finance/CFO 59 14-05-27
Andrei Shustov CTO
 Chief Tech/Sci/R&D Officer - 23-02-14
Jarrod Longcor COO
 Chief Operating Officer 51 16-07-14
Shane Lea PRN
 Corporate Officer/Principal - 22-11-20

Members of the board

Members of the board TitleAgeSince
Fred Driscoll BRD
 Director/Board Member 73 17-04-06
Douglas Swirsky CHM
 Chairman 54 17-04-06
John Neis BRD
 Director/Board Member 68 08-01-31
James V. Caruso CEO
 Chief Executive Officer 65 15-06-14
Stefan Loren BRD
 Director/Board Member 60 15-06-14
Asher Chanan-Khan BRD
 Director/Board Member 55 21-06-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 320 0 0 88.18 %
Stock B 0 111 0 0
Stock C 0 1,237 0 0
Stock D 1 32,260,510 28,446,406 ( 88.18 %) 0

Shareholders

NameEquities%Valuation
AIGH Capital Management LLC
21.67 %
2,662,324 21.67 % 11 M $
Rosalind Advisors, Inc.
16.32 %
2,005,658 16.32 % 8 M $
AIGH Capital Management LLC
15.59 %
1,915,220 15.59 % 8 M $
Adar1 Capital Management LLC
14.84 %
1,824,063 14.84 % 7 M $
Adar1 Capital Management LLC
11.21 %
1,378,082 11.21 % 5 M $
Nantahala Capital Management LLC
10.99 %
1,350,578 10.99 % 5 M $
Laurence Lytton
7.305 %
897,605 7.305 % 4 M $
Worth Venture Partners LLC
5.647 %
693,909 5.647 % 3 M $
Vanguard Global Advisers LLC
3.930 %
482,890 3.930 % 2 M $
Acuta Capital Partners LLC
3.886 %
477,500 3.886 % 2 M $

Company contact information

Cellectar Biosciences, Inc.

100 Campus Drive

07932, Florham Park

+608 441 8120

http://www.cellectar.com
address Cellectar Biosciences Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.06% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 321B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.36% 217B
NOVARTIS AG Stock Novartis AG
+6.19% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-8.96% 204B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CLRB Stock
  4. Stock
  5. Company Cellectar Biosciences Inc